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Role of HO-1 in renoprotection: Location, location, location
Heme oxygenase (HO)-1 is a ubiquitously expressed
enzyme that is induced by various stimuli, includ-
ing proinflammatory cytokines/endotoxin, hypoxia, is-
chemia/reperfusion, heat shock, heavy metals, and other
pathophysiologic responses that induce oxidative stress
[1, 2]. In many cell types, HO-1 has been shown to play
an important role in cellular protection against oxidant-
mediated cellular damage. HO-1 is the inducible isoform
of heme oxygenase, which catalyzes the degradation of
heme (a potent oxidant) to generate carbon monoxide (a
vasodilatory gas that has anti-inflammatory properties),
bilirubin (an antioxidant derived from biliverdin), and
iron (sequestered by ferritin) [1]. Due to the varied prop-
erties of HO-1 and its products of heme catabolism, HO-
1 has been therapeutically implicated in several disease
processes whose pathophysiologies involve inflammation
and oxidative stress, including atherosclerosis/vascular
injury, hypertension, endotoxic shock, acute renal injury,
transplant rejection, as well as others [2]. In recent years,
the use of HO-1 gene therapy has become an area of
intense investigation.
The kidney is an organ highly vulnerable to damage
caused by oxidative stress and reactive oxygen species.
Processes contributing to the progression of renal dys-
function into end-stage renal disease include hyperten-
sion, diabetes, polycystic kidney disease, and chronic
allograft rejection [3]. Other immunologic disorders of
the kidneys, ischemic insults, and nephrotoxic drugs also
lead to oxidative stress and subsequent renal injury. An-
tioxidant enzymes, as in many other organs, play impor-
tant protective roles in the kidney. HO-1 is one of these
enzymes induced in the kidney by oxidative stimuli in
an effort to resist injury. For example, HO-1 is induced
in animal models of acute renal injury such as glycerol-
induced renal failure, nephrotoxic serum nephritis, cis-
platin nephrotoxicity, and ischemia-induced renal failure
[4]. Increased expression of HO-1 has been noted in re-
nal tubules, renal glomeruli, and inflammatory cells in-
filtrating the kidney, depending on the model studied.
Moreover, chemical inhibitors of HO activity and HO-
1 null mice [5] have been shown to worsen renal dam-
age in some of these models, suggesting a protective role
for HO-1. Even though endogenous HO-1 appears to be
protective, an inadequate level or timing of endogenous
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HO-1 expression could compromise its full cytoprotec-
tive ability and not allow complete renoprotection and
prevention from progression to renal failure. Thus, mod-
ulation of HO-1 expression by exogenous gene transfer
is being studied in an attempt to improve the renoprotec-
tive capabilities of this cytoprotective enzyme.
In this issue of Kidney International, Quan et al [6] take
the story a step further to approach the therapeutic appli-
cation of HO-1 overexpression. Here they show that se-
lective up-regulation of HO-1 gene attenuates oxidative
stress caused by angiotensin II in primary cultured cells
of the thick ascending loop of Henle (TALH). The TALH
segment of the nephron is highly susceptible to ischemic
injury because of its location in the oxygen-poor medulla.
After infection of the cells with an adenoviral vector ex-
pressing human HO-1, the decrease in glutathione lev-
els by angiotensin II was attenuated, and TALH cell in-
jury and DNA damage were diminished. These results are
consistent with other reports showing the beneficial effect
of HO-1 in blocking inflammatory responses, oxidative
injury, and apoptosis in a variety of cell types [2]. How-
ever, not all types of cells respond to HO-1 up-regulation
in the same way. For instance, when assessing the effect
of HO-1 in vascular cells, overexpression can suppress
inflammation-induced apoptosis in endothelial cells, in
part caused by the generation of HO-1–derived carbon
monoxide production [7]. However, in vascular smooth
muscle cells (VSMC), a very different response occurs. In-
fection of VSMC with adenovirus expressing HO-1 leads
to apoptosis [8]. Interestingly, in VSMC, this response
appears to be related to the generation of bilirubin, not
carbon monoxide.
While previous studies have investigated the effect of
HO-1 gene therapy in the kidney using an adenoviral ap-
proach [9], in our opinion the most critical aspect of the
article by Quan et al [6] is the use of a cell type-specific
promoter (Na+-K+-Cl− cotransporter, or NKCC2) to
drive HO-1 expression in TALH, but not other cell types.
Efforts such as these will not only help to target HO-1 ex-
pression to cells most vulnerable to the pathophysiologic
insult being studied, but will also prevent the collateral
injury to bystander cells that may occur when selective
targeting is not used. Adding to the excitement of this
in vitro work is the fact that the NKCC2 promoter has
already been used to target the thick ascending limb of
the nephron in vivo [10].
Taking the work of Quan et al together with a multitude
of earlier HO-1 studies, we believe that optimizing the
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cytoprotective ability of HO-1 in gene targeting and gene
therapy will depend not only on the products of heme
catabolism, but also on (1) the specific cell type where
HO-1 is being targeted; (2) the level of HO-1 overexpres-
sion; (3) the timing and duration of HO-1 overexpression;
and (4) and the pathophysiologic stimulus that the cell is
being exposed to during HO-1 overexpression. Future
studies using this type of selective targeting approach in
animal models of disease will help to further elucidate
the potential of HO-1 as a renoprotective agent in hu-
man disease.
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